Olanzapine in treatment-resistant bipolar disorder

Susan L. McElroy, Mark A Frye, Kirk Denicoff, Lori Altshuler, Willem Nolen, Ralph Kupka, Trisha Suppes, Paul E. Keck, Gabrielle S. Leverich, Geri F. Kmetz, Robert M. Post

Research output: Contribution to journalArticle

107 Citations (Scopus)

Abstract

Background: We evaluated the response to olanzapine in 14 consecutive patients with bipolar I disorder who were inadequately responsive to standard psychotropic agents. Methods: Fourteen patients with bipolar I disorder by DSM-IV criteria experiencing persistent affective symptoms inadequately responsive to at least one standard mood stabilizer were treated with open- label olanzapine by one of the authors. Response was assessed with the Clinical Global Impression Scale modified for use in bipolar disorder (CGI- BP). Results: The 14 patients received olanzapine at a mean (SD dosage of 14.1 ± 7.2 (range 5-30) mg/day for a mean ± SD of 101.4 + 56.3 (range 30- 217) days of treatment. Of the 14 patients, 8 (57%) displayed much or very much overall improvement in their illness. In general, olanzapine was well tolerated. The most common side effects were sedation, tremor, dry mouth, and appetite stimulation with weight gain. Limitations: Data were obtained nonblindly and without a randomized control group, and olanzapine was added to ongoing psychotropic regimens. Conclusion: Olanzapine may have antimanic and mood-stabilizing effects in some patients with bipolar disorder, and is generally well tolerated. Controlled studies of olanzapine in bipolar disorder appear warranted.

Original languageEnglish (US)
Pages (from-to)119-122
Number of pages4
JournalJournal of Affective Disorders
Volume49
Issue number2
DOIs
StatePublished - May 1998
Externally publishedYes

Fingerprint

olanzapine
Bipolar Disorder
Therapeutics
Antimanic Agents
Affective Symptoms
Tremor
Appetite
Diagnostic and Statistical Manual of Mental Disorders
Weight Gain
Mouth

Keywords

  • Bipolar disorder
  • Olanzapine

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Behavioral Neuroscience
  • Biological Psychiatry
  • Neurology
  • Psychology(all)

Cite this

McElroy, S. L., Frye, M. A., Denicoff, K., Altshuler, L., Nolen, W., Kupka, R., ... Post, R. M. (1998). Olanzapine in treatment-resistant bipolar disorder. Journal of Affective Disorders, 49(2), 119-122. https://doi.org/10.1016/S0165-0327(98)00002-0

Olanzapine in treatment-resistant bipolar disorder. / McElroy, Susan L.; Frye, Mark A; Denicoff, Kirk; Altshuler, Lori; Nolen, Willem; Kupka, Ralph; Suppes, Trisha; Keck, Paul E.; Leverich, Gabrielle S.; Kmetz, Geri F.; Post, Robert M.

In: Journal of Affective Disorders, Vol. 49, No. 2, 05.1998, p. 119-122.

Research output: Contribution to journalArticle

McElroy, SL, Frye, MA, Denicoff, K, Altshuler, L, Nolen, W, Kupka, R, Suppes, T, Keck, PE, Leverich, GS, Kmetz, GF & Post, RM 1998, 'Olanzapine in treatment-resistant bipolar disorder', Journal of Affective Disorders, vol. 49, no. 2, pp. 119-122. https://doi.org/10.1016/S0165-0327(98)00002-0
McElroy, Susan L. ; Frye, Mark A ; Denicoff, Kirk ; Altshuler, Lori ; Nolen, Willem ; Kupka, Ralph ; Suppes, Trisha ; Keck, Paul E. ; Leverich, Gabrielle S. ; Kmetz, Geri F. ; Post, Robert M. / Olanzapine in treatment-resistant bipolar disorder. In: Journal of Affective Disorders. 1998 ; Vol. 49, No. 2. pp. 119-122.
@article{6ec0090dc2934a489bbc991e7cb93e7a,
title = "Olanzapine in treatment-resistant bipolar disorder",
abstract = "Background: We evaluated the response to olanzapine in 14 consecutive patients with bipolar I disorder who were inadequately responsive to standard psychotropic agents. Methods: Fourteen patients with bipolar I disorder by DSM-IV criteria experiencing persistent affective symptoms inadequately responsive to at least one standard mood stabilizer were treated with open- label olanzapine by one of the authors. Response was assessed with the Clinical Global Impression Scale modified for use in bipolar disorder (CGI- BP). Results: The 14 patients received olanzapine at a mean (SD dosage of 14.1 ± 7.2 (range 5-30) mg/day for a mean ± SD of 101.4 + 56.3 (range 30- 217) days of treatment. Of the 14 patients, 8 (57{\%}) displayed much or very much overall improvement in their illness. In general, olanzapine was well tolerated. The most common side effects were sedation, tremor, dry mouth, and appetite stimulation with weight gain. Limitations: Data were obtained nonblindly and without a randomized control group, and olanzapine was added to ongoing psychotropic regimens. Conclusion: Olanzapine may have antimanic and mood-stabilizing effects in some patients with bipolar disorder, and is generally well tolerated. Controlled studies of olanzapine in bipolar disorder appear warranted.",
keywords = "Bipolar disorder, Olanzapine",
author = "McElroy, {Susan L.} and Frye, {Mark A} and Kirk Denicoff and Lori Altshuler and Willem Nolen and Ralph Kupka and Trisha Suppes and Keck, {Paul E.} and Leverich, {Gabrielle S.} and Kmetz, {Geri F.} and Post, {Robert M.}",
year = "1998",
month = "5",
doi = "10.1016/S0165-0327(98)00002-0",
language = "English (US)",
volume = "49",
pages = "119--122",
journal = "Journal of Affective Disorders",
issn = "0165-0327",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Olanzapine in treatment-resistant bipolar disorder

AU - McElroy, Susan L.

AU - Frye, Mark A

AU - Denicoff, Kirk

AU - Altshuler, Lori

AU - Nolen, Willem

AU - Kupka, Ralph

AU - Suppes, Trisha

AU - Keck, Paul E.

AU - Leverich, Gabrielle S.

AU - Kmetz, Geri F.

AU - Post, Robert M.

PY - 1998/5

Y1 - 1998/5

N2 - Background: We evaluated the response to olanzapine in 14 consecutive patients with bipolar I disorder who were inadequately responsive to standard psychotropic agents. Methods: Fourteen patients with bipolar I disorder by DSM-IV criteria experiencing persistent affective symptoms inadequately responsive to at least one standard mood stabilizer were treated with open- label olanzapine by one of the authors. Response was assessed with the Clinical Global Impression Scale modified for use in bipolar disorder (CGI- BP). Results: The 14 patients received olanzapine at a mean (SD dosage of 14.1 ± 7.2 (range 5-30) mg/day for a mean ± SD of 101.4 + 56.3 (range 30- 217) days of treatment. Of the 14 patients, 8 (57%) displayed much or very much overall improvement in their illness. In general, olanzapine was well tolerated. The most common side effects were sedation, tremor, dry mouth, and appetite stimulation with weight gain. Limitations: Data were obtained nonblindly and without a randomized control group, and olanzapine was added to ongoing psychotropic regimens. Conclusion: Olanzapine may have antimanic and mood-stabilizing effects in some patients with bipolar disorder, and is generally well tolerated. Controlled studies of olanzapine in bipolar disorder appear warranted.

AB - Background: We evaluated the response to olanzapine in 14 consecutive patients with bipolar I disorder who were inadequately responsive to standard psychotropic agents. Methods: Fourteen patients with bipolar I disorder by DSM-IV criteria experiencing persistent affective symptoms inadequately responsive to at least one standard mood stabilizer were treated with open- label olanzapine by one of the authors. Response was assessed with the Clinical Global Impression Scale modified for use in bipolar disorder (CGI- BP). Results: The 14 patients received olanzapine at a mean (SD dosage of 14.1 ± 7.2 (range 5-30) mg/day for a mean ± SD of 101.4 + 56.3 (range 30- 217) days of treatment. Of the 14 patients, 8 (57%) displayed much or very much overall improvement in their illness. In general, olanzapine was well tolerated. The most common side effects were sedation, tremor, dry mouth, and appetite stimulation with weight gain. Limitations: Data were obtained nonblindly and without a randomized control group, and olanzapine was added to ongoing psychotropic regimens. Conclusion: Olanzapine may have antimanic and mood-stabilizing effects in some patients with bipolar disorder, and is generally well tolerated. Controlled studies of olanzapine in bipolar disorder appear warranted.

KW - Bipolar disorder

KW - Olanzapine

UR - http://www.scopus.com/inward/record.url?scp=18344409122&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18344409122&partnerID=8YFLogxK

U2 - 10.1016/S0165-0327(98)00002-0

DO - 10.1016/S0165-0327(98)00002-0

M3 - Article

C2 - 9609675

AN - SCOPUS:18344409122

VL - 49

SP - 119

EP - 122

JO - Journal of Affective Disorders

JF - Journal of Affective Disorders

SN - 0165-0327

IS - 2

ER -